PE20030747A1 - Agonistas del receptor 2 del factor liberador de la corticotropina - Google Patents

Agonistas del receptor 2 del factor liberador de la corticotropina

Info

Publication number
PE20030747A1
PE20030747A1 PE2003000039A PE2003000039A PE20030747A1 PE 20030747 A1 PE20030747 A1 PE 20030747A1 PE 2003000039 A PE2003000039 A PE 2003000039A PE 2003000039 A PE2003000039 A PE 2003000039A PE 20030747 A1 PE20030747 A1 PE 20030747A1
Authority
PE
Peru
Prior art keywords
agonists
releasing factor
corticotropin releasing
factor receptor
zeta
Prior art date
Application number
PE2003000039A
Other languages
English (en)
Inventor
Robert Joseph Isfort
Wieslaw Adam Mazur
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20030747A1 publication Critical patent/PE20030747A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UN PEPTIDO NO NATIVO DE FORMULA ALFA-BETA-GAMMA-DELTA- EPSILON-ZETA-ETA-THETA; ALFA ES X1X2X3X4X5X6; X1, X2, X3 ES A, E, D, G, N, P, Q, S, T, Z; X4 ES F, I, L, P, T, V; X5 ES A, I, P, S, T, V; X6 ES I, L, M, N; BETA ES SX8DX10; X8, X10 SON I, L, V; GAMMA ES X11X12X13; X11 ES P,S,T, V; X12 Y X13 SON A, NAFTILALANINA, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S , T, V, W, Y; DELTA ES X14X15X16; X14 ES I, L, M; X15 ES L, M; X16 ES S, N, Q, R, EPSILON ES X17X18X19X20X21; X17 ES V, I, L, T, K, E, N, Q; X18 ES L, M, V, A, T; X19 ES I, F, L, M; X20 ES D, E, N, H; X21 ES L, V, I, Q, M, R; ZETA ES X22X23X24X25; X22 ES A, D, E, S, T; X23 ES K, R; X24 ES A, H, M, N, Q, T, Y; X25 ES E, D, I, K, N, Q, R; ETA ES X26X27X28X29X30X31; X26 ES A, D, G, H, K, N, Q, S; X27 ES A, E, I, L, M, Q; X28 ES A, K, H, Q, R, V; X29 ES A, E, K, M, N, Q; X30 ES H, K, N, Q, R; X31 ES A, K; THETA ES X32X33X35X36X37X38X39X40X41; X32 ES A, E, H,T; X33 ES A, D, E, I, L, N, Q, R; X35 ES A, R; X36 ES E, H, I, K, L, N, Q, R; X37 ES F, I, L, M, Y; X38 ES L, F, M; X39 ES A, D, E, N, Q; X40 ES A, D, E, H, I, K, N, Q, R S, T; X41 ES A, F, I, V. LOS PEPTIDOS SON AGONISTAS DEL RECEPTOR 2 DEL FACTOR LIBERADOR DE CORTICOTROPINA Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DISTROFIA MUSCULAR, CAQUEXIA
PE2003000039A 2002-01-16 2003-01-14 Agonistas del receptor 2 del factor liberador de la corticotropina PE20030747A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34911702P 2002-01-16 2002-01-16
US37633702P 2002-04-29 2002-04-29
US38889502P 2002-06-14 2002-06-14
US41198802P 2002-09-19 2002-09-19

Publications (1)

Publication Number Publication Date
PE20030747A1 true PE20030747A1 (es) 2003-10-23

Family

ID=27617822

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2003000040A PE20030974A1 (es) 2002-01-16 2003-01-14 Agonistas del receptor 2 del factor liberador de la corticotropina
PE2003000039A PE20030747A1 (es) 2002-01-16 2003-01-14 Agonistas del receptor 2 del factor liberador de la corticotropina
PE2003000041A PE20030849A1 (es) 2002-01-16 2003-01-14 Agonistas del receptor 2 del factor liberador de la corticotropina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2003000040A PE20030974A1 (es) 2002-01-16 2003-01-14 Agonistas del receptor 2 del factor liberador de la corticotropina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2003000041A PE20030849A1 (es) 2002-01-16 2003-01-14 Agonistas del receptor 2 del factor liberador de la corticotropina

Country Status (30)

Country Link
US (7) US6936585B2 (es)
EP (4) EP1465921B1 (es)
JP (3) JP4508649B2 (es)
KR (3) KR100758857B1 (es)
CN (3) CN100391972C (es)
AR (3) AR038144A1 (es)
AT (4) ATE334147T1 (es)
AU (2) AU2003205197B2 (es)
BR (3) BR0306878A (es)
CA (3) CA2470743C (es)
CY (1) CY1106133T1 (es)
DE (4) DE60321730D1 (es)
DK (2) DK1465921T3 (es)
ES (4) ES2299701T3 (es)
HK (1) HK1078095A1 (es)
IL (5) IL162431A0 (es)
MA (3) MA27591A1 (es)
MX (3) MXPA04006885A (es)
MY (1) MY140306A (es)
NO (3) NO20043366L (es)
NZ (3) NZ533599A (es)
PE (3) PE20030974A1 (es)
PL (3) PL373529A1 (es)
PT (2) PT1465921E (es)
RU (1) RU2294333C2 (es)
SA (3) SA03230565B1 (es)
SI (1) SI1465921T1 (es)
TW (3) TW200302278A (es)
WO (3) WO2003062269A2 (es)
ZA (1) ZA200404995B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2427490A1 (en) * 2000-09-22 2002-03-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2005103690A2 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
BRPI0609460A2 (pt) * 2005-03-30 2010-04-13 Novartis Vaccines & Diagnostics Inc haemophilus influenzae tipo b
WO2007090087A2 (en) * 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
WO2009033773A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent
AU2008297874A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of secretin and optionally urodilatin as therapeutic agents
US10040838B2 (en) * 2008-11-04 2018-08-07 Janssen Pharmaceutica Nv CRHR2 peptide agonists and uses thereof
EP2206726A1 (en) * 2009-01-08 2010-07-14 Universite Joseph Fourier Non-invasive tools for detecting vulnerable atherosclerotic plaques
MX2012005262A (es) * 2009-11-04 2012-09-28 Janssen Pharmaceutica Nv Metodo para tratar la insuficiencia cardiaca con petidos tipo estrescopina.
WO2013063046A1 (en) 2011-10-24 2013-05-02 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
WO2013123094A2 (en) 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
MX2019004401A (es) * 2016-10-20 2019-09-26 Cortene Inc Metodos de tratamiento y enfermedades resultantes de una respuesta de tension mal adaptada.
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235036A (en) 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
EP0860501A3 (en) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Corticotropin-releasing factor2 receptors
US5786203A (en) 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
CA2223792A1 (en) 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
US5869450A (en) 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
AU2001284683B2 (en) 2000-08-04 2006-04-27 Research Development Foundation Urocortin proteins and uses thereof
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists

Also Published As

Publication number Publication date
PE20030849A1 (es) 2003-12-01
JP4489434B2 (ja) 2010-06-23
KR100758857B1 (ko) 2007-09-14
DE60313845D1 (de) 2007-06-28
MA27591A1 (fr) 2005-11-01
NZ533599A (en) 2007-03-30
JP2005525101A (ja) 2005-08-25
NZ533600A (en) 2007-02-23
PE20030974A1 (es) 2003-12-26
CN100391972C (zh) 2008-06-04
MY140306A (en) 2009-12-31
DK1465923T3 (da) 2007-07-02
US20030148956A1 (en) 2003-08-07
AU2003205197B2 (en) 2006-03-02
ATE398632T1 (de) 2008-07-15
CN1617886A (zh) 2005-05-18
US7192924B2 (en) 2007-03-20
BR0306838A (pt) 2005-04-05
CN1617887A (zh) 2005-05-18
DK1465921T3 (da) 2006-11-27
KR100735586B1 (ko) 2007-07-04
NO20043371L (no) 2004-10-06
ATE383372T1 (de) 2008-01-15
PT1465923E (pt) 2007-08-06
TWI300442B (en) 2008-09-01
KR20040082389A (ko) 2004-09-24
AU2003237419B2 (en) 2006-04-13
SA03230565B1 (ar) 2006-10-31
SA03230564A (ar) 2005-12-03
DE60321730D1 (de) 2008-07-31
US7192923B2 (en) 2007-03-20
US7462597B2 (en) 2008-12-09
US20030148957A1 (en) 2003-08-07
CN100475844C (zh) 2009-04-08
US7632933B2 (en) 2009-12-15
CA2470656A1 (en) 2003-07-31
ATE334147T1 (de) 2006-08-15
NO20043396L (no) 2004-10-06
US6936585B2 (en) 2005-08-30
EP1465921B1 (en) 2006-07-26
MA27590A1 (fr) 2005-11-01
ES2269976T3 (es) 2007-04-01
PL373139A1 (en) 2005-08-22
EP1724283A2 (en) 2006-11-22
PL371364A1 (en) 2005-06-13
MXPA04006884A (es) 2004-12-06
MXPA04006885A (es) 2004-12-06
WO2003062277A1 (en) 2003-07-31
JP2005522191A (ja) 2005-07-28
MXPA04006883A (es) 2004-12-06
RU2294333C2 (ru) 2007-02-27
WO2003062269A3 (en) 2003-11-06
ATE362488T1 (de) 2007-06-15
ES2287484T3 (es) 2007-12-16
DE60313845T2 (de) 2008-01-31
EP1724283B1 (en) 2008-06-18
TW200302278A (en) 2003-08-01
US7608701B2 (en) 2009-10-27
NZ533598A (en) 2007-03-30
ES2309909T3 (es) 2008-12-16
TW200302277A (en) 2003-08-01
US20060025339A1 (en) 2006-02-02
TW200302276A (en) 2003-08-01
EP1465923A1 (en) 2004-10-13
WO2003062268A3 (en) 2003-11-27
EP1465922A2 (en) 2004-10-13
IL196384A0 (en) 2011-07-31
WO2003062268A2 (en) 2003-07-31
IL162431A0 (en) 2005-11-20
SI1465921T1 (sl) 2006-10-31
SA03230564B1 (ar) 2006-10-31
BR0306826A (pt) 2005-09-06
CA2470731C (en) 2011-06-21
JP2005521387A (ja) 2005-07-21
EP1465921A2 (en) 2004-10-13
RU2004124847A (ru) 2005-04-20
AR038143A1 (es) 2004-12-29
DE60318547T2 (de) 2008-12-24
AR038144A1 (es) 2004-12-29
IL162530A0 (en) 2005-11-20
US20030148958A1 (en) 2003-08-07
KR20040082390A (ko) 2004-09-24
KR20040082392A (ko) 2004-09-24
US20090124793A1 (en) 2009-05-14
SA03230565A (ar) 2005-12-03
US20080004435A1 (en) 2008-01-03
ZA200404995B (en) 2005-06-29
CA2470743C (en) 2011-12-13
HK1078095A1 (en) 2006-03-03
PT1465921E (pt) 2006-12-29
CA2470656C (en) 2011-06-28
US20100197579A1 (en) 2010-08-05
CA2470731A1 (en) 2003-07-31
PL373529A1 (en) 2005-09-05
NO20043366L (no) 2004-10-06
DE60307044T2 (de) 2007-02-15
CN1617885A (zh) 2005-05-18
DE60307044D1 (de) 2006-09-07
WO2003062269A2 (en) 2003-07-31
ES2299701T3 (es) 2008-06-01
BR0306878A (pt) 2004-10-26
IL197774A0 (en) 2009-12-24
EP1465923B1 (en) 2007-05-16
JP4508649B2 (ja) 2010-07-21
AR038142A1 (es) 2004-12-29
EP1724283A3 (en) 2007-04-11
KR100758858B1 (ko) 2007-09-14
JP4508648B2 (ja) 2010-07-21
US7897731B2 (en) 2011-03-01
CA2470743A1 (en) 2003-07-31
DE60318547D1 (de) 2008-02-21
IL162529A0 (en) 2005-11-20
CY1106133T1 (el) 2011-06-08
EP1465922B1 (en) 2008-01-09
MA27592A1 (fr) 2005-11-01

Similar Documents

Publication Publication Date Title
PE20030747A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina
CR20210040A (es) Compuestos coagonistas de gip/glp1
IS7329A (is) Flúr setinn sýklóalkanóindól og notkun þeirra semprostaglandín D2 viðtaka mótlyfja
NO20080052L (no) G-Protein kopplede reseptoragonister
ATE466028T1 (de) N-terminal veränderte glp-1 abkömmlinge
ZA200409186B (en) Specific antibodies to amyloid beta peptide, pahrmaceutical compositions and methods of use thereof.
NO20053742L (no) Tri (cyclo)-substituerte amidforbindelser
CO5640143A2 (es) Formulaciones parenterales de un peptido para el tratamiento de lupus eritematoso sistematico
CL2008003847A1 (es) Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
MXPA06003474A (es) Agonistas de receptores de melanocortina.
PE20190355A1 (es) Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
DE50301242D1 (de) Distrahierbares wirbelsäulenimplantat
JP2005519059A5 (es)
GEP201706611B (en) Amido compounds and their use as pharmaceuticals
CR20220020A (es) Compuestos agonistas de gipr
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
FR2865373B1 (fr) Materiel d'osteosynthese vertebrale
DK1653950T3 (da) Nitrooxyderivater af Losartan, Valsatan, Candesartan, Telmisartan, Eprosartan og Olmesartan som angiotensin II-receptorblokkere til behandling af cardiovaskulære sygdomme
WO2007075377A3 (en) Certain chemical entities, compositions and methods
DK1553860T3 (da) Liggestol med en fodstöttemekanisme, der kan svinges op og strækkes ud
DE602005022571D1 (de) Hybrid-komposit aus polymer/bioaktivem keramik/zement
HRP20050024A2 (en) Pegylated t20 polypeptide
MX2022009149A (es) Compuestos coagonistas de gip/glp1.
DE60328157D1 (de) Bildausgabegerät mit Umwandlung der Auflösung

Legal Events

Date Code Title Description
FC Refusal